EMAIL THIS PAGE TO A FRIEND

Arzneimittel-Forschung

Comparative bioavailability of cefuroxime axetil suspension formulations administered with food in healthy subjects.


PMID 20329659

Abstract

To assess the comparative bioavailability of two formulations (250 mg/5 mL suspension) of cefuroxime axetil (CAS 64544-07-6), administered with food, in healthy volunteers of both sexes. The study was conducted using an open, randomized, two-period crossover design with a 1-week washout interval. Plasma samples were obtained for up to 12 h post dose. Plasma cefuroxime axetil concentrations were analyzed by liquid chromatography coupled with tandem mass spectrometry (LC-MS-MS) with negative ion electrospray ionization using multiple reactions monitoring (MRM). From the cefuroxime axetil plasma concentration vs. time curves, the following pharmacokinetic parameters were obtained: AUClast and Cmax. The limit of quantification was 0.1 microg/mL for plasma cefuroxime axetil analysis. The geometric mean and 90% confidence interval CI of test/reference product percent ratios were: 106.1% (100.8%-111.8%) for Cmax, 109.4% (104.8%-114.2%) for AUClast. Since the 90% CI for AUClast and Cmax ratios were within the 80-125% interval proposed by the US FDA, it was concluded that cefuroxime axetil (test formulation, 250 mg/5 mL suspension) was bioequivalent to a reference formulation under fed conditions, for both the rate and extent of absorption.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

A4237
Cefuroxime Axetil
C20H22N4O10S